Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Table 2 Univariate associations between cancer and other patient characteristics

Characteristic	Cancer patients		Non-cancer patients		Odds ratio	P
	% or mean (sd)	n	% or mean (sd)	n
Number of subjects		126		877
TZD therapy	32.5%	126	25.3%	877	1.42	0.09
Pioglitazone	13.5%	126	13.6%	877	0.99	0.98
Rosiglitazone	19.1%	126	11.9%	877	1.75	0.03
Sulfonylurea therapy	34.9%	126	38.2%	877	0.87	0.48
Biguanide therapy	39.7%	126	40.0%	877	0.99	0.94
Nateglinide therapy	0.8%	126	0.5%	877	1.75	0.62
Men	42.1%	126	46.1%	877	0.85	0.40
Age, years	69.1 (10.2)	126	64.2 (12.1)	877	1.04	<0.001
White ethnicity	97.6%	125	97.3%	875	1.15	0.83
A1C, mean %	7.0 (1.3)	126	7.2 (1.3)	871	0.88	0.12
Insulin therapy	15.9%	126	18.8%	877	0.81	0.43
Body mass index, kg/m²	32.7 (6.8)	125	34.0 (7.5)	865	0.97	0.06
Alcohol drinking	25.4%	126	27.6%	876	0.89	0.60
Cigarette smoking	11.1%	126	17.8%	876	0.58	0.06
Median annual income, $	15000–29999	114	15000–29999	813	1.02	0.75
Duration of diabetes, years	10.2 (9.7)	124	10.2 (10.4)	829	1.00	0.98
High comorbidity	71.4%	126	46.2%	877	2.91	<0.001
Number of prescription medications	7.3 (4.3)	126	6.6 (3.7)	877	1.05	0.05
Number of anti-diabetic drugs	1.2 (1.0)	126	1.2(0.9)	877	1.01	0.92
Physical functional status	40.9 (13.7)	125	42.3 (12.7)	871	0.99	0.27
Mental functional status	50.5 (10.5)	126	49.4 (10.9)	875	1.01	0.30

sd, standard deviation; n, number of patients for which data were available; TZD, thiazolidinedione.

ISSN: 1741-7015